Jefferies Financial Group Inc. Invests $48,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT)

Jefferies Financial Group Inc. purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 14,800 shares of the company’s stock, valued at approximately $48,000.

Other large investors also recently bought and sold shares of the company. Fairmount Funds Management LLC bought a new position in shares of Inhibikase Therapeutics during the fourth quarter valued at approximately $19,906,000. Blackstone Inc. purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter worth approximately $6,730,000. Caxton Corp purchased a new stake in shares of Inhibikase Therapeutics in the 4th quarter worth approximately $53,000. Nantahala Capital Management LLC bought a new position in Inhibikase Therapeutics during the 4th quarter valued at approximately $7,118,000. Finally, Northern Trust Corp purchased a new position in Inhibikase Therapeutics during the fourth quarter valued at $208,000. 3.81% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Inhibikase Therapeutics in a report on Friday, March 28th.

Inhibikase Therapeutics Stock Performance

Shares of Inhibikase Therapeutics stock opened at $2.01 on Monday. The company has a 50-day simple moving average of $2.11 and a two-hundred day simple moving average of $2.49. Inhibikase Therapeutics, Inc. has a 52-week low of $1.12 and a 52-week high of $4.20. The stock has a market capitalization of $149.43 million, a PE ratio of -0.75 and a beta of 1.01.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.